Abstract
Several thiazolidinedione classes of compounds (drugs) found to be very effective in reducing insulin resistance or to efficiently potentiate insulin action in type 2 non insulin-dependent diabetes mellitus (NIDDM) patients; the structure-activity relationship of such related compounds, similar to ciglitazone, giving rise to the development of troglitazone, englitazone, pioglitazone and rosiglitazone as new drug entities for diabetes, and several studies showing that analogs of these classes interact with a nuclear receptor PPARyand transcript the insulin sensitizing genes form the subject-matter of this review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zenodo (CERN European Organization for Nuclear Research)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
